NeoPharm Presents Results of IL13-PE38QQR Multicenter Phase I Studies

NeoPharm has presented updated combined data from three Phase I studies of cintredekin besudotox (IL13-PE38QQR) in brain cancer patients.

The combined data included results from 51 patients from three clinical studies in which peritumoral Convection Enhanced Delivery of cintredekin besudotox following tumor resection was evaluated. The overall median survival for the 45 patients in the three studies who received peritumoral infusion of cintredekin besudotox is 44 weeks.

Six patients from the studies remain progression free, with a survival range of 39 to 190 weeks (median 89 weeks) after a single treatment. In addition, optimal catheter placement appears to further improve median survival.